For men losing their hair, a new discovery by researchers at
Boston University
School of Medicine (BUSM) might prompt them to opt out of
treating their impending baldness.
5a-reductase inhibitors (or "5a-RIs"), commonly used to treat
urinary problems in patients with benign prostatic hyperplasia
(BPH) and found in the popular medication Propecia to treat hair
loss, has been found to produce loss of libido, erectile
dysfunction (ED), ejaculatory dysfunction, gynecomastia (breast
enlargement in males), and potential depression in some
patients.
Extreme caution
These findings suggest doctors should exercise extreme caution
prior to prescribing 5a-RIs therapy to patients for hair growth or
for BPH symptoms.
"Furthermore, treatment of hair loss, a benign condition with 5a-RIs may produce persistent side effects in a number of young patients," he added.
5a-RIs, finasteride (Propecia) and dutasteride, have been approved for treatment of lower urinary tract symptoms, due to BPH, with marked clinical efficacy. Finasteride is also approved for treatment of hair loss (androgenetic alopecia).
Although the adverse side effects of these agents are thought to be minimal, the magnitude of adverse effects on sexual function, gynecomastia, depression, and quality of life remains ill-defined.
Prolonged adverse effects
In order to determine the potential extent of this problem, the
researchers examined the data reported in various clinical studies
concerning the side effects of finasteride and dutasteride.
After a review of the literature the researchers found that in a
subset of men, prolonged adverse effects on sexual function such as
erectile dysfunction and diminished libido were reported, raising
the possibility of a connection.
According to the researchers, the adverse side effects of 5a-RIs on
sexual function, gynecomastia and the impact on the overall health
have received minimal attention.
However, in some patients, these side effects are persistent with
regard to sexual function and with an emotional toll including
decreased quality of life.
Counseling recommended
"Honest and open discussion with patients to educate them on
these serious issues must be pursued prior to commencing therapy
because, in some patients, these adverse effects are persistent and
may be prolonged and patients do not recover well after
discontinuation from drug use," said Traish.
The researchers believe additional clinical and preclinical studies
are warranted to determine the reason for why some of these adverse
effects persist in some individuals.
Colleagues of the BUSM researchers at the Lahey Clinic and from
Denmark and Germany also collaborated on this study which currently
appears on-line in Journal of Sexual Medicine.